

Notification of attendance and form for advance voting

The form must be received by Egetis Therapeutics no later than October 21, 2024.

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in Egetis Therapeutics AB (publ), Reg. No. 556706–6724 at the extraordinary general meeting on October 25, 2024. The voting right is exercised in accordance with the voting options marked below.

Shareholder	Personal identity number/registration number

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): The undersigned solemnly declare that the enclosed power of attorney corresponds to the original and has not been revoked.

Place and date	
Signature	
Clarification of signature	
Telephone number	E-mail

Instructions

- Complete all the requested information above
- Select the preferred voting options below
- Print, sign and send the form by post to Egetis Therapeutics, Klara Norra Kyrkogata 26, SE-111 22, Stockholm, Sweden or via e-mail to info@egetis.com
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign
- If the shareholder votes by proxy, a proxy shall be enclosed to the form. If the shareholder is a legal entity, a certificate of incorporation or an equivalent certificate of authority should be enclosed to the form

A shareholder whose shares have been registered in the name of a bank or securities institute must register its shares in its own name to vote. Instructions for this is included in the notice convening the extraordinary general meeting.

A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (*i.e.* the advance vote in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented.

The advance voting form, together with any enclosed authorisation documentation, shall be provided to Egetis Therapeutics no later than October 21, 2024. An advance vote can be withdrawn up to and including October 21, 2024, by contacting Egetis Therapeutics via e-mail to info@egetis.com.

One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by Egetis Therapeutics will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered. If a shareholder has voted in advance and attends the extraordinary general meeting in person or through a proxy, the advance vote is still valid except to the extent the shareholder participates in a voting procedure at the extraordinary general meeting or otherwise withdraws its casted advance vote. If the shareholder chooses to participate in a voting at the extraordinary general meeting, the vote cast will replace the advance vote with regard to the relevant item on the agenda.

Note that the advance vote does not constitute a notification to participate in the extraordinary general meeting at the venue in person or through proxy. Instructions for shareholders who wish to participate in the extraordinary general meeting at the venue in person or represented by a proxy are included in the notice convening the extraordinary general meeting.

For the complete proposals, kindly refer to the notice convening the extraordinary general meeting and the company's website www.egetis.com.

For information on how your personal data is processed, see the integrity policy that is available at <https://www.egetis.com> and at Euroclear's website, www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Extraordinary general meeting in Egetis Therapeutics AB (publ) on October 25, 2024

The options below comprise the submitted proposals included in the notice convening the extraordinary general meeting and are held available on the company's website.

2. Election of chairman of the general meeting
2.1 Dain Hård Nevonen Yes ☐ No ☐
4. Approval of the agenda Yes ☐ No ☐
6. Determination of whether the extraordinary general meeting has been duly convened Yes ☐ No ☐
7. Resolution on approval of the Board of Directors' resolution on new issue of ordinary shares Yes ☐ No ☐